真性红细胞增多症与原发性血小板增多症:2017年诊断、风险分层和管理更新
该综述更新了真性红细胞增多症(PV)和原发性血小板增多症(ET)的诊断、预后及风险分层管理。PV诊断基于JAK2突变,ET驱动突变为JAK2、CALR和MPL。风险分层指导治疗,羟基脲为两者降细胞治疗一线药物。
要点
- PV诊断需JAK2突变,其缺失且血清促红细胞生成素正常或升高时诊断可能性小。
- ET中JAK2、CALR、MPL突变发生率分别为55%、25%、3%,约17%为三阴性。
- PV和ET中位生存期分别约14年和20年,年轻患者(<60岁)分别为24年和33年。
核心结论
- PV和ET的主要治疗目标是预防血栓出血并发症。
研究设计与样本
- 综述总结了PV和ET的诊断、风险分层和管理更新。
主要发现
- PV中位生存期约14年,ET约20年;年轻患者(<60岁)分别为24年和33年。
- 20年白血病转化率PV估计<10%,ET为5%;纤维化转化率略高。
- ET中JAK2/MPL突变与动脉血栓风险较高相关,MPL突变与纤维化进展风险较高相关。
- PV中ASXL1、SRSF2和IDH2突变与较差总生存、无白血病或无线维化生存相关;ET中不良突变包括SH2B3、SF3B1、U2AF1、TP53、IDH2和EZH2。
关键数值与推荐
- PV高风险:年龄>60岁或血栓史;低风险:两者均无。
- ET风险分层:极低危(年龄≤60岁,无血栓史,JAK2/MPL未突变)、低危(年龄≤60岁,无血栓史,JAK2/MPL突变)、中危(年龄>60岁,无血栓史,JAK2/MPL未突变)、高危(血栓史或年龄>60岁伴JAK2/MPL突变)。
- 极端血小板增多(血小板>1000×10⁹/L)可能与获得性血管性血友病综合征(AvWS)相关,出血风险增加。
- 所有PV患者需放血治疗使血细胞比容低于45%,并每日一次阿司匹林(81 mg);高风险PV患者还需降细胞治疗。
- 极低危ET患者可能无需治疗;低危ET患者至少每日一次阿司匹林;高危ET推荐降细胞治疗,中危非必须。
临床怎么用
- PV患者需放血使血细胞比容<45%并每日阿司匹林81 mg,高风险者加用降细胞治疗。
- ET按风险分层治疗:极低危可能无需治疗,低危用阿司匹林,高危推荐降细胞治疗。
- 降细胞治疗一线用羟基脲,二线用干扰素-α或白消安。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. DIAGNOSIS: PV is defined by a JAK2 mutation, whose absence, combined with normal or increased serum erythropoietin level, makes the diagnosis unlikely. JAK2, CALR, and MPL mutations are the mutually exclusive "driver" mutations in ET with respective incidences of 55%, 25%, and 3%; approximately 17% are triple-negative. However, the same molecular markers might also be present in prefibrotic myelofibrosis, whose morphological distinction from ET is prognostically relevant. SURVIVAL AND LEUKEMIC/FIBROTIC TRANSFORMATION: Median survivals are approximately 14 years for PV and 20 years for ET; the corresponding values for younger patients (age <60 years) are 24 and 33 years. Life-expectancy in ET is inferior to the control population. Driver mutational status has not been shown to affect survival in ET whereas the presence of JAK2/MPL mutations has been associated with higher risk of arterial thrombosis and that of MPL with higher risk of fibrotic progression. Risk factors for overall survival in both ET and PV include advanced age, leukocytosis and thrombosis. Leukemic transformation rates at 20 years are estimated at <10% for PV and 5% for ET; fibrotic transformation rates are slightly higher. Most recently, ASXL1, SRSF2, and IDH2 mutations have been associated with inferior overall, leukemia-free or fibrosis-free survival in PV; similarly adverse mutations in ET included SH2B3, SF3B1, U2AF1, TP53, IDH2, and EZH2. THROMBOSIS RISK STRATIFICATION: Current risk stratification in PV and ET is designed to estimate the likelihood of recurrent thrombosis. Accordingly, PV includes two risk categories: high-risk (age >60 years or thrombosis history) and low-risk (absence of both risk factors). In ET, risk stratification includes four categories: very low risk (age ≤60 years, no thrombosis history, JAK2/MPL un-mutated), low risk (age ≤60 years, no thrombosis history, JAK2/MPL mutated), intermediate risk (age >60 years, no thrombosis history, JAK2/MPL un-mutated), and high risk (thrombosis history or age >60 years with JAK2/MPL mutation). In addition, presence of extreme thrombocytosis (platelets >1000 × 10(9)/L) might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding. RISK-ADAPTED THERAPY: The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily aspirin (81 mg). In addition, high-risk patients with PV require cytoreductive therapy. Very low risk ET patients might not require any form of therapy while low-risk patients require at least once-daily aspirin therapy. Cytoreductive therapy is also recommended for high-risk ET patients but it is not mandatory for intermediate-risk patients. First-line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second-line drugs of choice are interferon-α and busulfan. We currently do not recommend treatment with ruxolutinib or other JAK2 inhibitors in PV or ET, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs. Screening for AvWS is recommended before administrating aspirin, in the presence of extreme thrombocytosis. Am. J. Hematol. 92:95-108, 2017. © 2016 Wiley Periodicals, Inc.
引用
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017. PMID: 27991718. doi:10.1002/ajh.24607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。